TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH LOW-DOSE INTRAVENOUS RECOMBINANT INTERLEUKIN-2
- Assess the response rate and survival of patients with metastatic renal cell carcinoma
treated with low-dose intravenous interleukin-2.
- Assess the toxicity associated with this treatment.
OUTLINE: Patients receive low-dose intravenous interleukin-2 every 8 hours for a maximum of
15 doses in week 1 and again in week 3. Stable and responding patients receive a second
course beginning approximately 2 months after initiation of the first course. Responding
patients may continue therapy every 2 months provided toxicity is limited.
Patients whose diseased kidney comprises the bulk of the tumor burden at entry undergo
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 14 patients will be accrued for this study.
Primary Purpose: Treatment
Richard L. White, MD
Blumenthal Cancer Center at Carolinas Medical Center
United States: Federal Government
|Carolinas Medical Center||Charlotte, North Carolina 28232-2861|